Analysts await Nevro Corp. (NASDAQ:NVRO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.58 EPS, down 1.72% or $0.01 from last year’s $-0.57 per share.

At the moment 7 analysts are watching Nevro Corp. (NASDAQ:NVRO), 1 rate it “Buy”, 5 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 6 analysts have a mean sales target of 39.56 million. For the quarter ending Sep-16, 6 analysts have a mean sales target of 40.79 million whilst for the year ending Dec-16, 7 analysts have a mean target of 165.97 million.

In terms of earnings per share, 7 analysts have a -0.63 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 7 analysts have a -0.56 EPS mean target and for the quarter ending Sep-16 there are 7 estimates of -2.25 EPS.

The biggest institutional shareholders in Nevro Corp. include Fidelity Management and Research Company which owns 4 million shares in the company valued at $242.38 million. Johnson & Johnson is the second biggest holder with 2 million shares currently valued at 139.53 million whilst AllianceBernstein LP has 2 million shares valued at 131.01 million.

Total shares held by institutions as of the most recent company filings are 25,865,124 with a reported 3,442,372 bought and 4,128,037 sold. These holdings make up 92.21% of the company’s outstanding shares.

Currently insiders hold 666,465 shares in the business which makes up 2.37% of shares. The biggest holder currently is Mr. Michael F. Demane who owns 552,587 shares (1.96% of those outstanding), whilst Mr. Rami Elghandour holds 64,180 (0.23% of shares outstanding) and Mr. Frank M. Fischer holds 59,000 (0.21% of shares outstanding).

The stock decreased 1.62% or $1.03 during the last trading session, hitting $99.99. Nevro Corp. (NASDAQ:NVRO) has risen 52.66% over the past 6 months and is uptrending.